192,339 Shares in Kyverna Therapeutics, Inc. $KYTX Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 192,339 shares of the company’s stock, valued at approximately $1,808,000. Simplify Asset Management Inc. owned about 0.44% of Kyverna Therapeutics as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new position in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $14,100,000. Vanguard Group Inc. grew its position in Kyverna Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after acquiring an additional 9,858 shares during the last quarter. Millennium Management LLC increased its holdings in Kyverna Therapeutics by 21.9% during the 3rd quarter. Millennium Management LLC now owns 551,635 shares of the company’s stock valued at $3,310,000 after purchasing an additional 99,075 shares in the last quarter. RFG Advisory LLC acquired a new stake in Kyverna Therapeutics during the 4th quarter valued at $4,185,000. Finally, Woodline Partners LP bought a new position in Kyverna Therapeutics in the 3rd quarter valued at $1,513,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Price Performance

Shares of NASDAQ KYTX opened at $8.67 on Monday. Kyverna Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $13.67. The firm’s 50-day moving average is $9.05 and its 200-day moving average is $8.44. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $527.05 million, a PE ratio of -2.64 and a beta of 2.05.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. Equities analysts expect that Kyverna Therapeutics, Inc. will post -2.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wall Street Zen upgraded Kyverna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. JPMorgan Chase & Co. decreased their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, HC Wainwright raised their price objective on shares of Kyverna Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.